Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups.

ABSTRACT: Evidence of clinical utility is a key issue in translating pharmacogenomics into clinical practice. Appropriately designed randomized controlled trials generally provide the most robust evidence of the clinical utility, but often only data from a pharmacogenomic association study are available. This paper details a method for reframing the results of pharmacogenomic association studies in terms of the comparative treatment effect for a pharmacogenomic subgroup to provide greater insight into the likely clinical utility of a pharmacogenomic marker, its' likely cost effectiveness, and the value of undertaking the further (often expensive) research required for translation into clinical practice. The method is based on the law of total probability, which relates marginal and conditional proba

SUBMITTER: Sorich MJ 

PROVIDER: S-EPMC3754999 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature